No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777Phase 4Completed64 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Dihydroergotamine (DHE) - Then and Now: A Narrative Review.

Silberstein Stephen D, Shrewsbury Stephen B, Hoekman John · Headache · 2020

PMID: 31737909Meta-AnalysisFull text (PMC)

Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.

Kellerman Donald J, Forst Amy, Combs Daniel L et al. · J Aerosol Med Pulm Drug Deliv · 2013

PMID: 23273242Meta-Analysis

Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

Morren John A, Galvez-Jimenez Nestor · Expert Opin Pharmacother · 2010

PMID: 21080856Meta-Analysis

Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.

Colman Ian, Brown Michael D, Innes Grant D et al. · Ann Emerg Med · 2005

PMID: 15795718Meta-Analysis

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.

Bodie Susan, Curran Aidan K, Gonzalez-Nelson Aaron C et al. · Headache · 2024

PMID: 38717120RCT

A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.

Lipton Richard B, Albrecht Detlef, Bermudez Maria et al. · Headache · 2024

PMID: 38413540RCT

MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.

Tepper Stewart J, Kori Shashidhar H, Goadsby Peter J et al. · Mayo Clin Proc · 2011

PMID: 21964172RCTFull text (PMC)

Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.

Dafer Rima M, Tietjen Gretchen E, Rothrock John F et al. · Headache · 2024

PMID: 38800847Trial

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.

Tepper Stewart J, Albrecht Detlef, Ailani Jessica et al. · CNS Drugs · 2024

PMID: 39373843TrialFull text (PMC)

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.

Smith Timothy R, Winner Paul, Aurora Sheena K et al. · Headache · 2021

PMID: 34363701TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dihydroergotamine (substance)
SNOMED CT: 387267005
UMLS CUI: C0012291
RxNorm CUI: 3418

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.